* Bristol-Myers Squibb Co., of New York, made anadditional equity investment of $5 million in CadusPharmaceutical Corp., of Tarrytown, N.Y., related to amilestone reached from their July 1994 collaboration.They are developing assays that measure signaltransduction through G protein-coupled receptors.
* ICOS Corp., of Seattle, said a PDE5 inhibitor it isdeveloping with London-based Glaxo Wellcome plc is inPhase I trials in the U.K. It is being evaluated forcongestive heart failure, angina and male erectiledisorder.
* Immunex Corp., of Seattle, released preliminary resultsfrom a cohort of 60 high-risk premature infants in a PhaseIII study that showed Leukine reduced infections. Seriousinfections occurred in 5 of 29 (17 percent) of infantsgiven Leukine compared to 12 of 31 (39 percent) in theplacebo group.
* ImmunoGen Inc., of Cambridge, Mass., hiredPaineWebber Inc., of New York, to help it achieve itspartnering objectives.
* IMRE Corp., of Seattle, said the FDA conditionallyapproved a 268-patient pivotal trial of its Prosorbacolumn for the treatment of rheumatoid arthritis.
* NeXstar Pharmaceuticals Inc., of Boulder, Colo.,acquired patent rights to MiKasome, its liposomalformulation of the antibiotic amikacin, from AmpliMedCorp., of Tucson, Ariz., by reducing its stake inAmpliMed to 19.9 percent and agreeing to pay royaltieson sales.
* SunPharm Corp., of Jacksonville, Fla., entered acollaboration with the University of Toronto's ClarkInstitute of Psychiatry to study SunPharm's polyamineanalogue drugs in patients with Alzheimer's disease.
(c) 1997 American Health Consultants. All rights reserved.